Get started
Author

Polyn Luz S Pine

Observed names: P L S Pine, P.L.S., Pine, Pine, Polyn Luz, Pine, Polyn Luz S., Polyn Luz Pine, Polyn Luz S. Pine
OpenAlex ID: A5113330211
Participation of Women in Cardiovascular Trials From 2017 to 2023
2025 · Frederick Berro Rivera, John Vincent Magalong, et al. · JAMA Network Open · 43
PDF
Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials
2024 · Frederick Berro Rivera, Marielle Nicole Cabusas Chin, et al. · Current Medical Research and Opinion · 14
Evaluating the safety profile of semaglutide: an updated meta-analysis
2024 · Frederick Berro Rivera, Eloise Arias-Aguirre, et al. · Current Medical Research and Opinion · 11
Enrollment of Females in Randomized Trials for Glucagon-Like Peptide 1 Receptor Agonists
2024 · Frederick Berro Rivera, Mc John Caro Ybañez, et al. · JACC Advances · 9
Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials
2024 · Frederick Berro Rivera, Nathan Ross B. Bantayan, et al. · Journal of clinical lipidology · 9
Sex Disparity in the In-Hospital Outcomes of Patients with Kidney Disease Admitted for Myocardial Infarction: Insights from a Large National Database
2024 · Frederick Berro Rivera, Jade Monica Marie Ruyeras, et al. · Cardiorenal Medicine · 4
Valvular Heart Disease Interventional Trials From 2000 to 2024
2025 · Frederick Berro Rivera, Chieh-Mei Tsai, et al. · JACC Advances · 2
Trends and Predictors of Premature Termination of Cardiovascular Trials
2026 · Frederick Berro Rivera, Nathan Ross B. Bantayan, et al. · JACC Advances · 1
Participation of women in cardiovascular trials from 2017 to 2023: a systematic review
2025 · M Gulati, F B Rivera, et al. · European Heart Journal · 1
Enrollment of all-female and lactating or pregnant female participants in cardiovascular trials
2025 · Polyn Luz S. Pine, Frederick Berro Rivera, et al. · npj Cardiovascular Health · 1
PDF
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction–associated steatotic liver disease
2026 · Nicole Ann Tesoro, Frederick Berro Rivera, et al. · American Journal of Preventive Cardiology
26-a-12430-acc Effects of Glp-1 Receptor Agonists and Dual Agonists on Alcohol Use Disorder: a Meta-analysis and Systematic Review
2026 · Nicole Ann Tesoro, Frederick Rivera, et al. · Journal of the American College of Cardiology
26-a-9870-acc Trends and Predictors of Premature Termination of Cardiovascular Trials
2026 · Frederick Rivera, Nicole Ann Tesoro, et al. · Journal of the American College of Cardiology
26-a-12618-acc Impact of Glp-1 Receptor Agonists and Dual Agonists on Liver Enzymes and Imaging Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (masld): a Systematic Review
2026 · Nicole Ann Tesoro, Frederick Rivera, et al. · Journal of the American College of Cardiology
PDF
Abstract 4346523: Enrollment Trends and Demographic Representation in Valvular Heart Disease Interventional Trials from 2000 to 2024: A Systematic Review
2025 · Chieh-Mei Tsai, Frederick Rivera, et al. · Circulation
Abstract 4146295: Sex disparity in the in-hospital outcomes of patients with chronic kidney disease admitted for ST elevation myocardial infarction: Insights from a large national database
2024 · Frederick Rivera, Jade Monica Marie Ruyeras, et al. · Circulation
Impact of Chronic Kidney Disease on the Outcomes of Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Insights from a Large National Database
2024 · Frederick Berro Rivera, Sung Whoy Cha, et al. · Cardiorenal Medicine
Works count: 20
Citation count: 95
H-index: 5
I10-index: 3
Year
Topic
Type